Altmetric

The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.

Title: The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.
Authors: Eng, PC
Distaso, W
Durreshahwar, H
Shaikhali, Y
Narendranathan, D
Cassin-Scott, R
Misra, S
Hill, NE
Tharakan, G
Oliver, NS
Tan, TM
Izzi-Engbeaya, C
Salem, V
Item Type: Journal Article
Abstract: Dexamethasone significantly reduces mortality1 and is now standard treatment for patients with COVID-19 who require supplemental oxygen and/or mechanical ventilation. However, supraphysiological doses of glucocorticoids may exacerbate dysglycaemia and precipitate hyperglycaemic complications, particularly in those with or at risk of Type 2 diabetes2. The RECOVERY trial1 reported a low incidence of hyperglycaemic complications (2/1996, 0.1%), although the real-world incidence is likely to be much higher3. Type 2 diabetes itself increases the risk of severe COVID-194, and hyperglycaemia independently predicts poor outcomes5. We investigated the possibility that patients with diabetes may derive less survival benefit from steroid therapy in the setting of severe COVID-19 infection
Issue Date: 15-Mar-2022
Date of Acceptance: 12-Mar-2022
URI: http://hdl.handle.net/10044/1/96015
DOI: 10.1111/dom.14692
ISSN: 1462-8902
Publisher: Wiley
Start Page: 1385
End Page: 1389
Journal / Book Title: Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics
Volume: 24
Issue: 7
Copyright Statement: © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
Funder's Grant Number: RDF01
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
COVID-19
dexamethasone
diabetes
mortality
COVID-19
dexamethasone
diabetes
mortality
COVID-19
dexamethasone
diabetes
mortality
1103 Clinical Sciences
Endocrinology & Metabolism
Publication Status: Published
Conference Place: England
Online Publication Date: 2022-03-15
Appears in Collections:Department of Metabolism, Digestion and Reproduction
Bioengineering
Faculty of Medicine
Imperial College London COVID-19
Faculty of Engineering



This item is licensed under a Creative Commons License Creative Commons